Dual blockade of IL-17A and IL-36 pathways via a bispecific antibody exhibits enhanced anti-inflammatory potency.

MLA

Ma, Xiaojuan, et al. “Dual Blockade of IL-17A and IL-36 Pathways via a Bispecific Antibody Exhibits Enhanced Anti-Inflammatory Potency.” Frontiers in Immunology, vol. 15, Nov. 2024, p. 1434127. EBSCOhost, https://doi.org/10.3389/fimmu.2024.1434127.

APA

Ma, X., Zhang, S., Ren, X., Feng, Y., Li, H., Chen, S., Xu, J., Wang, Y., Peng, G.-Y., Yan, Q., Jia, H., Xia, S., Cui, X., Chen, X., Pan, X., Wang, S., Yu, H., Wei, X., Li, M., … Lu, L. (2024). Dual blockade of IL-17A and IL-36 pathways via a bispecific antibody exhibits enhanced anti-inflammatory potency. Frontiers in Immunology, 15, 1434127. https://doi.org/10.3389/fimmu.2024.1434127

Chicago

Ma, Xiaojuan, Shuang Zhang, Xiaochen Ren, Yujie Feng, Hui Li, Shi Chen, Jingen Xu, et al. 2024. “Dual Blockade of IL-17A and IL-36 Pathways via a Bispecific Antibody Exhibits Enhanced Anti-Inflammatory Potency.” Frontiers in Immunology 15 (November): 1434127. doi:10.3389/fimmu.2024.1434127.